Across TCGA pan-cancer cohorts, RPL23AP89 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RPL23AP89 data layer.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RPL23AP89 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL23AP89 expression acts as an unfavorable survival marker, although some lineages such as DLBC show a favorable association.
STAD, SKCM, and KIRP are the cancer types where RPL23AP89 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.